Literature DB >> 15892087

Reduced oxidative stress in parallel to improved cardiac performance one year after selective removal of anti-beta 1-adrenoreceptor autoantibodies in patients with idiopathic dilated cardiomyopathy: data of a preliminary study.

Ingolf Schimke1, Johannes Müller, Michael Dandel, Heinz-Detlef Gremmels, Wolfgang Bayer, Barbara Wallukat, Gerd Wallukat, Roland Hetzer.   

Abstract

Patients with idiopathic dilated cardiomyopathy (IDC) were treated with selective immunoadsorption to remove anti-beta 1-adrenoreceptor autoantibodies (anti-beta1A-AB). After one year, the effect on cardiac performance and oxidative stress was tested. Extracorporeal immunoadsorption of the whole IgG class in IDC patients for the removal of anti-beta1A-AB reduced oxidative stress in parallel to an improvement of cardiac performance. However, the non-specificity of IgG adsorption means that these beneficial effects cannot be attributed exclusively to anti-beta1A-AB removal. In an open clinical pilot study enrolling 8 patients with IDC prior to and one year after selective immunoadsorption of anti-beta1A-AB, plasma markers for oxidative stress--thiobarbituric acid-reactive substances (TBARS), lipid peroxides (LPO) and anti-oxidized low-density lipoprotein autoantibodies (anti-oxLDL-AB)--were measured in parallel to evaluation of the left ventricular function using conventional echocardiography and wall motion analysis by tissue Doppler imaging. After one year, TBARS (Wilcoxon test with bootstrapping simulation for paired data: 95% confidence interval of the P value 0.020 to 0.029) and anti-oxLDL-AB (P = 0.025 to 0.035) were decreased in parallel to an improvement of the peak systolic wall motion velocity (P = 0.006 to 0.01) and left ventricular ejection fraction (P = 0.002 to 0.02). For changes over the study period, a direct correlation with borderline significance (P = 0.076) was calculated for TBARS to the left ventricular diameter in the diastole. One year after selective immunoadsorption for anti-beta1A-AB removal, patients with ICD show a reduction in oxidative stress and a parallel improvement in cardiac performance. Copyright 2005 Wiley-Liss, Inc

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15892087     DOI: 10.1002/jca.20050

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  9 in total

Review 1.  The clinical significance of anti-beta-1 adrenergic receptor autoantibodies in cardiac disease.

Authors:  Udi Nussinovitch; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

Review 2.  Autoantibodies and cardiovascular dysfunction: cause or consequence?

Authors:  Yuji Nagatomo; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2014-12

Review 3.  Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases.

Authors:  Gerd Wallukat; Ingolf Schimke
Journal:  Semin Immunopathol       Date:  2014-04-29       Impact factor: 9.623

Review 4.  Targeting anti-beta-1-adrenergic receptor antibodies for dilated cardiomyopathy.

Authors:  Priyesh A Patel; Adrian F Hernandez
Journal:  Eur J Heart Fail       Date:  2013-05-02       Impact factor: 15.534

Review 5.  Autoimmunological features in inflammatory cardiomyopathy.

Authors:  Angela Kallwellis-Opara; Andrea Dörner; Wolfgang-Christian Poller; Michel Noutsias; Uwe Kühl; Heinz-Peter Schultheiss; Mathias Pauschinger
Journal:  Clin Res Cardiol       Date:  2007-05-22       Impact factor: 5.460

6.  Autoantibodies and Cardiomyopathy: Focus on Beta-1 Adrenergic Receptor Autoantibodies.

Authors:  Wai Hong Wilson Tang; Sathyamangla V Naga Prasad
Journal:  J Cardiovasc Pharmacol       Date:  2022-09-01       Impact factor: 3.271

7.  Increased circulating β2-adrenergic receptor autoantibodies are associated with smoking-related emphysema.

Authors:  Jia-Yi Hu; Bei-Bei Liu; Yi-Peng Du; Yuan Zhang; Yi-Wei Zhang; You-Yi Zhang; Ming Xu; Bei He
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

8.  Unmasking features of the auto-epitope essential for β1 -adrenoceptor activation by autoantibodies in chronic heart failure.

Authors:  Angela Wölfel; Mathias Sättele; Christina Zechmeister; Viacheslav O Nikolaev; Martin J Lohse; Fritz Boege; Roland Jahns; Valérie Boivin-Jahns
Journal:  ESC Heart Fail       Date:  2020-05-21

9.  Oxidized Low-Density Lipoprotein Serum Concentrations and Cardiovascular Morbidity in End Stage of Renal Disease.

Authors:  Vaia Raikou; Vasilios Kardalinos; Despina Kyriaki
Journal:  J Cardiovasc Dev Dis       Date:  2018-06-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.